Effect of pirenzepine, a new gastric acid-inhibiting agent, on exocrine pancreatic secretion in man.
The effect of orally ingested 5,1-dihydroxy-11- (4-methyl-1-piperazinyl)-acetyl-6H-pyrido(2,3-b)-I, 4-benzodiazepin-6-one dihydrochloride (LS 519, pirenzepine), a newly developed compound with gastric secretion-inhibitory action but without central-nervous sedation, on the secretion of fluid into the duodenum and on pancreatic enzyme output was studied by a marker perfusion technique in 10 human subjects. A short-lasting increase in duodenal volume was observed, while output of trypsin and lipase remained unchanged. Central and autonomic nervous actions seem unlikely, a possible release of endogenous secretion was discussed.tin was discussed.
D001569:Benzodiazepines / Q000494:pharmacology*; D003864:Depression, Chemical; D005750:Gastric Juice / Q000378:metabolism*; D006801:Humans; D008049:Lipase / Q000378:metabolism; D010179:Pancreas / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism*; D010189:Pancreatic Juice / Q000378:metabolism; D010879:Piperazines; D012633:Secretin / Q000494:pharmacology; D013997:Time Factors; D014357:Trypsin / Q000378:metabolism
D010879:Piperazines; D001569:Benzodiazepines; D012633:Secretin; D008049:Lipase; D014357:Trypsin